Skip to main content
SpringerLink
Log in

Severe asthma phenotypes and targeted therapy: news from the 25th European Respiratory Society international congress, 26–30 September, Amsterdam

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

This report highlights information presented at the 2015 European Respiratory Society international congress, with a focus on selected presentations on the complexity of asthma, efforts to phenotype the disease and the clinical development of monoclonal antibodies to treat severe asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2015. Bethesda: Global Initiative for Chronic Obstructive Lung Disease, Inc.; 2015.

  2. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–25.

    Article  CAS  PubMed  Google Scholar 

  3. Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015;46(5):1322–33.

    Article  PubMed  Google Scholar 

  4. Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–21.

    Article  PubMed  Google Scholar 

  5. Hekking PP, Loza MJ, Pavlidis S, et al. Transcriptomic fingerprinting in severe adult-onset asthma shows type2-high and inflammatory-cell gene signatures in the U-BIOPRED cohort [abstract no. OA291]. Eur Respir J. 2015;46(Suppl 59).

  6. Ingenito E, Bigler J, Smith D, et al. Characteristics of asthma in U-BIOPRED severe and non-severe cohorts with distinct biomarker profiles [abstract no. PA2546]. Eur Respir J. 2015;46(Suppl 59).

  7. Hoda U, Sousa AR, Corfield J, et al. Characteristics of the frequent exacerbator in U-BIOPRED adult severe asthma cohort [abstract no. OA1461]. Eur Respir J. 2015;46(Suppl 59).

  8. Pavlidis S, Loza M, Baribaud F, et al. Th2 subsetting of U-BIOPRED asthma subjects based on airway transciptomic profiles [abstract no. OA1772]. Eur Respir J. 2015;46(Suppl 59).

  9. Keating GM. Mepolizumab: first global approval. Drugs. 2015;75(18):2163–9.

    Article  CAS  PubMed  Google Scholar 

  10. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66.

    Article  CAS  PubMed  Google Scholar 

  11. Brusselle G, Germarino M, Eid S, et al. Reslizumab in patients with late-onset asthma with elevated blood eosinophils [abstract no. OA287]. Eur Respir J. 2015;46(Suppl 59).

  12. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–90.

    Article  CAS  PubMed  Google Scholar 

  13. Damera G, Brightling C, Bleeker E, et al. Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia [abstract no. PA2118]. Eur Respir J. 2015;46(Suppl 59).

  14. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3(9):692–701.

    Article  CAS  PubMed  Google Scholar 

  15. Brightling CE, Nordenmark LH, Jain M, et al. Effect of anti-IL-13 treatment on airway dimensions in severe asthma: subgroup analysis [abstract no. PA2119]. Eur Respir J. 2015;46(Suppl 59).

  16. Ranade R, Manetz S, Liang M, et al. Effect of tralokinumab on serum periostin and IgE levels in uncontrolled severe asthma [abstract no. OA1770]. Eur Respir J. 2015;46(Suppl 59).

  17. Jeanblanc N, Manetz S, Lee R, et al. A new investigational use only automated immunoassay for periostin [abstract no. PA3936]. Eur Respir J. 2015;46(Suppl 59).

  18. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–56.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Cai F, Choy DF, Brumm J, et al. Serum IL-13 is a peripheral biomarker for Type 2 asthma [abstract no. PA4364]. Eur Respir J. 2015;46(Suppl 59).

  20. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.

    Article  CAS  PubMed  Google Scholar 

  21. Wenzel S, Castro M, Zhang B, et al. A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): final data [abstract no. OA289]. Eur Respir J. 2015;46(Suppl 59).

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Rod McNab

Authors
  1. Rod McNab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rod McNab.

Ethics declarations

Funding

The preparation of this article was not supported by any external funding.

Conflicts of interest

R. McNab is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McNab, R. Severe asthma phenotypes and targeted therapy: news from the 25th European Respiratory Society international congress, 26–30 September, Amsterdam. Drugs Ther Perspect 32, 156–161 (2016). https://doi.org/10.1007/s40267-016-0284-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0284-7

Keywords

Search

Navigation